Mikaela Weeder

Ms. Mikaela Weeder

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2022 in Journal of Animal Science
Verified
Journal Article
Open access
PDF file
MMMiriam Martin
Miriam Martin
MKMichael Kleinhenz
Michael Kleinhenz
LELily Edwards-Callaway
Lily Edwards-Callaway
TETerry Engle
Terry Engle
OGOctavio Guimaraes
Octavio Guimaraes
Johann CoetzeeJohann Coetzee
Johann Coetzee
Hot-iron branding uses thermal injury to permanently identify cattle causing painful tissue damage. The primary objective was to examine the physiological and behavioral effects of oral meloxicam (MEL), compared to a control, administered at the time of hot-iron branding in Angus and Hereford steers and heifers. The secondary objectives were to investigate breed and sex effects on pain biomarkers. A total of 70 yearlings, consisting of 35 heifers and 35 steers (Angus, Hereford, or Angus × Hereford), were enrolled in the study. Animals were blocked by sex, randomized across weight, and assigned to receive MEL (1 mg/kg) or a placebo (CON). Biomarkers were assessed for 48 h after branding and included infrared thermography (IRT), mechanical nociceptive threshold (MNT), accelerometry and a visual analog scale (VAS), and serum cortisol and prostaglandin E2 metabolites (PGEM). Wound healing was assessed for 12 wk. Hair samples to quantify cortisol levels were taken prior to and 30 d post-branding. Responses were analyzed using repeated measures with calf nested in treatment as a random effect, and treatment, time, treatment by time interaction, breed, and sex as fixed effects. There was a treatment by time interaction for PGEM (P < 0.01) with MEL having lower values than CON at 6, 24, and 48 h (MEL: 18.34 ± 3.52, 19.61 ± 3.48, and 22.24 ± 3.48 pg/mL, respectively; CON: 32.57 ± 3.58, 37.00 ± 3.52, and 33.07 ± 3.48 pg/mL; P < 0.01). MEL showed less of a difference in maximum IRT values between the branded (2.27 ± 0.29 °C) and control site (3.15 ± 0.29 °C; P < 0.01). MEL took fewer lying bouts at 0–12 h (4.91 bouts ± 0.56) compared with CON (6.87 bouts ± 0.55; P < 0.01). Compared with Hereford calves, Angus calves exhibited greater serum but lower hair cortisol, greater PGEM, more lying bouts, and less healed wound scores at 3, 4, and 5 wk. Compared with heifers, steers exhibited lower PGEM, lower branding site and ocular IRT, higher MNT, and lower plasma meloxicam levels. Steers spent more time lying, took more lying bouts and had greater VAS pain, and more healed wound scores at 5 wk than heifers. Meloxicam administration at branding reduced branding and control site temperature differences and reduced lying bouts for the first 12 h. Breed and sex effects were observed across many biomarkers. Changes from baseline values for IRT, MNT, lying time, step count, VAS pain, and wound scoring all support that branding cattle is painful. Hot-iron branding uses thermal injury to permanently identify cattle causing painful tissue damage. The primary objective was to examine the effects of oral meloxicam (MEL), compared with a control, administered at the time of hot-iron branding in Angus and Hereford steers and heifers. The secondary objectives were to investigate breed and sex effects on pain biomarkers. A total of 70 yearlings, consisting of 35 heifers and 35 steers (Angus, Hereford, or Angus × Hereford), were enrolled. Animals were assigned to receive MEL or a placebo. Changes from baseline values for infrared thermography (IRT), mechanical nociceptive threshold, lying time, step count, visual analog scale score, and wound scoring all support that hot-iron branding cattle is painful and investigation into analgesic strategies is needed. MEL administration reduced IRT differences from the branding and control site and reduced lying bouts. Breed and sex effects were observed across a wide range of biomarkers and should be considered in future pain studies. The practicality of administering a nonsteroidal anti-inflammatory drug once at the time of branding is attractive. However, a multimodal approach using a combination of analgesics or longer acting analgesic option warrants further investigation to alleviate pain and discomfort caused by hot-iron branding.

1 January 2023 in Translational Animal Science
Verified
Journal Article
Open access
PDF file
MWMikaela Weeder
Mikaela Weeder
MKMichael Kleinhenz
Michael Kleinhenz
EREmily J Reppert
Emily J Reppert
BFBailey R Fritz
Bailey R Fritz
AVAbbie V Viscardi
Abbie V Viscardi
Johann CoetzeeJohann Coetzee
Johann Coetzee
Lameness continues to be a critical health and welfare concern associated with goat production. Amphotericin B (amp B) is an antimicrobial successful in inducing transient lameness for research purposes previously in livestock animals. The objectives of this study were to (1) identify which of three varying doses of amp B would be most effective in inducing lameness in meat type goats and (2) develop a facial grimace scale for goats. Lameness was produced by an intra-articular injection of amphotericin B into the left hind lateral claw distal interphalangeal joint with either a 5 mg/0.25 mL (high–low, 5 mg of amphotericin B in a volume of 0.25 mL), 5 mg/0.5 mL (high–high, 5 mg of amphotericin B in a volume of 0.5 mL), or a 2.5 mg/0.25 mL (low–low, 2.5 mg of amphotericin B in a volume of 0.25 mL). A saline treatment of 0.5 mL was used as control (0.9% sterile saline solution). Lameness response was analyzed by infrared thermography (IRT) at the induced joint, mechanical-nociception threshold (MNT), visual lameness scoring (VLS), a visual analogue scale (VAS), kinetic gait analysis (KGA), plasma cortisol (CORT), substance P (Sub P), and behavior scoring. The IRT and MNT values differed by timepoint (P ≤ 0.0001). Results from VLS showed the HL treatment was the most effective at inducing lameness (6/6 goats became lame compared to HH 4/6 and LL 2/6). At 24, 48, and 72 h, VAS scores were significantly higher when comparing HL to all other treatment groups (P = 0.0003). Both behavior observers (1 and 2) reported a significant time effect (P = 0.05), with goats exhibiting more facial grimacing at 24 h post-lameness induction. From these data, an optimal dose for a repeatable lameness induction model in goats was aquired. An effective Goat Grimace Scale (GGS) was also developed to evaluate pain responses in goats.

7 October 2022 in Animals
Verified
Journal Article
Open access
PDF file
ACAndrew Curtis
Andrew Curtis
DJDouglas E. Jones
Douglas E. Jones
MKMichael Kleinhenz
Michael Kleinhenz
SMShawnee Montgomery
Shawnee Montgomery
MMMiriam Martin
Miriam Martin
Johann CoetzeeJohann Coetzee
Johann Coetzee
Immunocastration relies on the vaccine-mediated stimulation of an immune response to gonadotropin-releasing hormone (GnRH) in order to interrupt spermatogenesis. This approach offers a less painful alternative to traditional castration approaches but the current, commercially available options require multiple doses of vaccine to maintain sterility. Thus, a series of pilot studies were conducted to determine the feasibility of a single-dose immunocastration vaccine implant. These five studies utilized a total of 44 Holstein bulls to determine the optimal vaccine composition and validate the ability of a stainless-steel subcutaneous implant to deliver a vaccine. Outcome measures included the duration of implant retention, scrotal dimensions and temperature, implant site temperature, anti-GnRH antibodies, and serum testosterone concentration. Over the course of several studies, anti-GnRH antibodies were successfully stimulated by vaccine implants. No significant treatment effects on scrotal dimensions or testosterone were detected over time, but changes in spermatogenesis were detected across treatment groups. Results indicate that a single-dose implantable immunocastration vaccine elicits a humoral immune response and could impact spermatogenesis in bulls. These findings provide opportunities for the refinement of this technology to improve implant retention over longer periods of time. Taken together, this approach will offer producers and veterinarians an alternative to physical castration methods, to improve animal welfare during routine livestock management procedures.

1 March 2024 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Open access
MKMichael Kleinhenz
Michael Kleinhenz
DDDarian Davis
Darian Davis
MWMikaela Weeder
Mikaela Weeder
ALAlyssa Leslie
Alyssa Leslie
EREmily J. Reppert
Emily J. Reppert
Johann CoetzeeJohann Coetzee
Johann Coetzee
Gabapentin is used in goats to treat chronic pain associated with lameness. However, pharmacokinetic data and clinical effectiveness trials are lacking. The objective of the study was to describe the pharmacokinetics of gabapentin in goats following a single oral dose. Six Spanish‐crossbred goats were enrolled. Each goat was administered gabapentin at a target dose of 15 mg/kg per os. Serial blood samples were collected out to 60 h post‐gabapentin administration for plasma gabapentin concentration determination. Plasma samples were analyzed for gabapentin concentration using ultra‐high‐pressure liquid chromatography coupled with mass spectroscopy. Individual animal pharmacokinetic outcomes were determined using non‐compartmental analysis. Gabapentin was detectable in the plasma of all goats at 60 h post‐administration. The mean (±SD) Cmax was 2.01 ± 0.62 μg/mL which occurred at 8.47 ± 1.9 h. The mean terminal half‐life (T1/2) and mean resident time were determined to be 8.52 ± 1.8 and 18.7 ± 4.0 h, respectively. This study indicates gabapentin is absorbed from the gastrointestinal tract of goats. Further research is needed to determine an optimal dose for clinical efficacy in goats.

1 October 2025 in American Journal of Veterinary Research
Verified
Journal Article
Open access
MWMikaela Weeder
Mikaela Weeder
MKMichael Kleinhenz
Michael Kleinhenz
EREmily J. Reppert
Emily J. Reppert
ACAndrew Curtis
Andrew Curtis
AVAbbie V. Viscardi
Abbie V. Viscardi
Johann CoetzeeJohann Coetzee
Johann Coetzee
Objective: This study evaluated the analgesic effects of firocoxib, meloxicam, and transdermal flunixin in meat-type goats with experimentally induced lameness. Methods: 44 crossbred castrated meat-type goats with an average weight of 35 kg (range, 25 to 43 kg) were enrolled from June to December 2022. Lameness was induced with amphotericin B injected in the distal interphalangeal joint of the left hind lateral claw. After a washout period, lameness was reproduced in the right hind limb. Eleven treatment groups were implemented: firocoxib (0.5, 1.0, and 2.0 mg/kg), meloxicam (1.0, 2.0, and 3.0 mg/kg, transdermal flunixin (3.3, 4.2, and 5.0 mg/kg), and positive and negative control. Outcome measurements included infrared thermography, mechanical nociception threshold, plasma cortisol, plasma substance P, kinetic gait analysis, visual lameness scoring, and visual analog scoring and were collected at –24, 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours relative to lameness induction. Results: Transdermal flunixin at 3.3 and 5.0 mg/kg demonstrated the greatest analgesic effects from outcome measurements collected. Conclusions: Transdermal flunixin meglumine provides the most effective analgesia for goats with induced lameness, suggesting it may be the preferred option for pain relief in goats with lameness symptoms. Clinical Relevance: Transdermal flunixin meglumine at 3.3 or 5.0 mg/kg provided the best results for pain mitigation in goats with induced lameness.

1 October 2025 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Open access
HNHannah M. Neill
Hannah M. Neill
EREmily J. Reppert
Emily J. Reppert
MKMichael Kleinhenz
Michael Kleinhenz
MWMikaela Weeder
Mikaela Weeder
DSDane Schwartz
Dane Schwartz
AVAbbie V. Viscardi
Abbie V. Viscardi
Objective: To examine behavioral and physiologic outcomes associated with the expression of pain in calves with naturally occurring neonatal calf diarrhea (NCD) and determine the impact of meloxicam administration on reducing these pain-related behaviors and outcomes. Methods: Beef calves 3 to 30 days old with NCD and no comorbidities or prior NSAID or steroid administration were enrolled as clinical cases, and healthy beef calves were enrolled as controls. Clinical cases received either meloxicam (MEL group) or placebo (PLBO group) treatment; all controls received placebo. Over 7 time points, outcomes measured were substance P, prostaglandin E metabolite, mechanical nociceptive threshold, gait analysis, behavior analysis, physical examinations, and intake bloodwork. Results: 20 calves with NCD and 8 healthy calves were enrolled. Prostaglandin E metabolite was significantly higher in calves with NCD than controls. Control calves were more reactive to pressure over the hip than calves with NCD, particularly those treated with meloxicam. Calves with NCD had shorter stride length and slower gait velocity compared to controls. Calves with NCD spent more time lying and more time lying with their head up compared to controls. Calves in the MEL group spent more time lying with their head down compared to PLBO calves. Conclusions: Differences in mechanical nociceptive threshold, gait analysis, and lying behavior possibly indicated the presence of abdominal pain. Differences in head posture between MEL and PLBO calves suggest that calves treated with meloxicam may have been more comfortable. Clinical Relevance: Calves with NCD may experience pain, and treating them with meloxicam may relieve that pain.